Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
Quick Look: AstraZeneca has raised its Japan approval target to more than 50 by 2030, up from a previous goal of 40, with seven filings under review and late-stage assets advancing. Japan sales in 2025 remained virtually flat, slipping 0.1%…
To read the full story
Related Article
- AstraZeneca Names Andy Barnett as New Japan President
February 3, 2026
- AstraZeneca Eyes 40 Approvals by 2030 in Japan, Driven by New Modalities
April 15, 2025
- AstraZeneca’s Japan Sales Up 8.2% in 2023 Despite Nexium Patent Cliff
March 27, 2024
- AstraZeneca Japan Grows 17% in 2022, Bags 12 Approvals; Up to 7 Filings Eyed for 2023
April 14, 2023
- AstraZeneca Japan Taps Ex-Takeda Japan Oncology Head as New Chief
July 4, 2022
- AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
BUSINESS
- SSP Looks to Broaden Switch OTC Portfolio under New President
April 13, 2026
- Nippon Shinyaku, xFOREST Ink RNA-Targeting Small Molecule Research Pact
April 13, 2026
- OTC-Like Drug Reform Seen Adding 190 Billion Yen to Japan OTC Market by 2040: Fuji Keizai
April 13, 2026
- AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
- MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…